Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D-Reference-Cited by-同舟云学术

Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D

Published:2015-03 Issue:2 Volume:11 Page:e190-e198
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Davidoff Amy J.¹,Hendrick Franklin B.¹,Zeidan Amer M.¹,Baer Maria R.¹,Stuart Bruce C.¹,Shenolikar Rahul A.¹,Gore Steven D.¹

Affiliation:

1. Yale School of Public Health, Yale University; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Maryland School of Pharmacy; Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD; and US Health Outcomes and Medical Policy, GlaxoSmithKline, Durham, NC

Abstract

Improved coordination between Part B and D benefits regarding issues of home injection of medications may create incentives that improve patient access and convenience.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2014.001527

Reference11 articles.

1. Saving Medicare through Patient-Centered Changes — The Case of Injectables

2. Management of RBC-Transfusion Dependence

3. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

4. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes

5. The Value of Specialty Oncology Drugs

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Low-Income Subsidies and Inequities in Orally Administered Antimyeloma Therapy Use;The American Journal of Managed Care;2023-05-01

2. Management of the Older Patient with Myelodysplastic Syndrome;Drugs & Aging;2021-08-03

3. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options;Cancer Management and Research;2021-01

4. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma;Journal of Clinical Oncology;2017-10-10

5. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia;American Journal of Hematology;2015-08-14